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Stent Position Is More Important than α-Blockers or Anticholinergics 
for Stent-Related Lower Urinary Tract Symptoms after 
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Dae Yul Yang, Sang Kon Lee, Jin Seon Cho
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Purpose: To evaluate the clinical factors that impact ureteral stent-related lower uri-
nary tract symptoms (LUTS) after ureteroscopic ureterolithotomy, including the stent 
position and medication.
Materials and Methods: Fifty-three patients who underwent ureteroscopic ureteroli-
thotomy with indwelling a stent were distributed into three groups. On demand an-
algesics were given to the group 1 (n=18). Daily tamsulosin 0.2 mg was added for group 
2 (n=15) and daily tamsulosin 0.2 mg and tolterodine 4 mg was added for group 3 (n=20). 
The patients were also subclassified into appropriate or inappropriate group according 
to stent position. All the patients completed a visual analogue scale (VAS) and Interna-
tional Prostate Symptom Score (IPSS) on the 1st and 7th postoperative days. The VAS 
and IPSS were analyzed according to the medication groups and the stent position.
Results: In the appropriate stent potion group, only the storage symptom scores of 
groups 2 and 3 on the 1st postoperative day were significantly lower than those of the 
group 1 (p=0.001). This medication effect on LUTS was not observed in the in-
appropriate stent position group. In this group, total IPSS (p=0.015) and storage symp-
tom scores (p=0.002) were higher than in the appropriate stent position group on the 
7th postoperative day.
Conclusions: Correct placement of the stent was more important than medication for 
lessening stent-related storage symptoms.
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INTRODUCTION
Placement of ureteral stents has been a common urological 
intervention since the first description of a cystoscopically 
placed endoluminal stent by Zimskind et al [1]. However, 
complications and morbidities associated with ureteral 
stents have been documented. In particular, general health 
and work performance are often affected by bothersome 
urinary symptoms (78%) and pain (80%) [2]. 
　In an attempt to minimize the morbidity of stents, some 
authors postulated that the length and position have to be 
adequate [3,4]. Some authors suggested that the use of α1- 
blockers and anticholinergics would be effective. Tamsulosin 
acts as a selective inhibitor of α-1a and 1-d-mediated con-
traction of the distal ureter, bladder trigone, and proximal 
urethral smooth muscle [5]. It is thought that relaxing 
these smooth muscles decreases bladder outlet resistance 
and voiding pressure, thereby decreasing renal reflux and 
voiding symptoms. Tolterodine has been shown to have 
functional selectivity for muscarinic receptor subtypes for 
the bladder and is strongly indicated for treating patients 
with overactive bladder (OAB) [6,7]. Korean J Urol 2010;51:636-641
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FIG. 1. The position of the ureteral 
stent. (A) The distal curling of the ure-
teral stent is positioned in the ipsila-
teral side. (B) The distal curling of the 
ureteral stent crossed the midline of 
the bladder.
　The use of α1-blockers and anticholinergics to prevent 
stent-related symptoms is based on the similarity of these 
symptoms to benign prostatic hyperplasia-related lower 
urinary tract symptoms (LUTS), including urgency, fre-
quency, and suprapubic pain, which are caused by in-
voluntary contraction of the bladder mediated by muscar-
inic receptors. Tamsulosin and tolterodine are effective for 
the treatment of men with LUTS among patients with BPH 
and OAB [5]. Therefore, we evaluated the clinical factors 
that impact ureteral stent-related LUTS after uretero-
scopic ureterolithotomy, including stent position and med-
ication with α-blockers and/or anticholinergics.
MATERIALS AND METHODS
With the approval of our Institutional Review Board, all pa-
tients signed an informed consent form before participating. 
From June 2008 to July 2009, patients who underwent ure-
teroscopic ureterolithotomy for symptomatic ureteral cal-
culi were enrolled prospectively. A total of 56 patients were 
enrolled and 3 patients were excluded. One patient refused 
to participate further, one met the exclusion criteria of uri-
nary tract infection, and the ureteral stone failed to be re-
moved in the last patients so he underwent open ureter-
olithotomy later. The 53 patients were randomly assigned 
into three groups. In group 1, 18 patients were prescribed 
analgesics only as a control. Fifteen patients in group 2 
were given 0.2 mg of tamsulosin and analgesics daily, and 
20 patients in group 3 took 0.2 mg of tamsulosin and 4 mg 
of tolterodine daily in addition to analgesics. All patients 
completed a visual analogue scale (VAS) for evaluation of 
pain and International Prostate Symptom Score (IPSS) for 
evaluation of LUTS. The patients were requested to com-
plete the questionnaires on the 1st and 7th postoperative 
days to assess stent-related LUTS and pain.
　The patients with a history of previous pelvic surgery and 
prostate surgery, evidence of urinary tract infection, chronic 
medication with α-blockers or anticholinergics, and severe 
complications during the procedure were excluded. Ure-
teroscopic ureterolithotomy was performed with a Wolf 
7.5/9 Fr dual operating channel semirigid ureteroscope, and 
intracorporeal lithotripsy was performed with a pneumatic 
lithotripter (50-60 Hz). A 6 Fr ureteral stent (Percuflex
Ⓡ 
material with Hydroplus
TM, Boston Scientific, MA, USA) 
was inserted in all patients after stone removal, and the 
length of the ureteral stent was adjusted according to the 
patient’s height. The location of the distal curling of the ure-
teral stents was evaluated postoperatively by plain KUB 
(Fig. 1A). When the distal curling exceed the midline 
(symphysis pubis), the stent was considered to be in an in-
appropriate position (Fig. 1B). The stents were removed at 
the outpatient department by use of a rigid 17.5 Fr cysto-
scope 2 or 3 weeks after ureteroscopic surgery according to 
the difficulty of the surgery. On-demand use of ketorolac 
tromethamine 10 mg was prescribed for pain control when 
the patients were discharged. All consenting patients were 
fully informed regarding the potential side effects of the 
medication.
　Statistical analysis was performed by using chi-square 
and ANOVA tests with commercially available software 
(Stata 11, StataCorp LP, TX, USA), and p＜0.05 was con-
sidered statistically significant.
RESULTS
Fifty-three patients completed the study protocol (Fig. 2). 
No significant statistical differences were observed in the 
clinicopathological characteristics among the patients in 
the three groups (Table 1). The mean age of the patients 
was 45 years (range, 20-80 years), and 36 patients (68%) 
were male. Baseline LUTS did not differ significantly 
among the groups. Korean J Urol 2010;51:636-641
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TABLE 2. Symptom changes among the groups
POD Group 1
a Group 2
b (p-value
d)G r o u p  3
c (p-value
d)p - v a l u e
No. of patients 18 15 20
Total IPSS 1 14.5±6.9 8.9±9.4 (0.186) 10.1±6.8 (0.129) 0.103
7 14.2±8.6 13.4±11.1 (0.997) 9.5±7.5 (0.570) 0.544
Voiding symptom score  1 6.9±4.8 5.0±5.8 (0.699) 5.7±5.0 (0.613) 0.594
7 6.9±5.4 7.5±7.2 (0.940) 5.1±4.5 (0.923) 0.788
Storage symptom score  1 7.6±3.9 3.9±4.6 (0.038) 4.4±2.8 (0.023) 0.014
7 7.2±4.1 5.9±5.1 (0.799) 4.4±3.3 (0.217) 0.244
QoL score  1 3.9±1.1 2.9±1.8 (0.324) 3.8±1.6 (0.596) 0.341
7 3.8±1.6 3.6±1.8 (0.991) 2.8±1.8 (0.447) 0.428
Visual pain scale (cm)  1 4.6±2.5 3.6±2.7 (0.469) 5.4±2.9 (0.987) 0.356
7 3.7±2.4 3.4±2.7 (0.987) 3.6±2.4 (0.975) 0.938
POD: postoperative day, IPSS: International Prostate Symptom Score, QoL: quality of life, 
a: control group, patients were prescribed
analgesics only, 
b: patients were given 0.2 mg of tamsulosin and analgesics daily, 
c: patients took 0.2 mg of tamsulosin and 4 mg of tolter-
odine daily in addition to analgesics, 
d: p-value compared with group 1 by Student’s t-test
FIG. 2. Study flow diagram.
TABLE 1. Baseline patient characteristics
Group 1
a Group 2
b Group 3
c p-value
No. of patients  18 15 20 -
Age (years) 45.0±18.1 43.3±11.3 46.4±13.0 0.831
Sex (male %)  66.7 66.7 70.0 0.969
Mean IPSS 8.7±6.9 9.5±8.6 6.3±6.9 0.386
Voiding symptom score 4.6±3.6 4.7±4.8 3.4±3.1 0.431
Storage symptom score 4.1±4.3 4.7±4.8 2.7±4.1 0.448
QoL score 2.9±1.9 2.2±1.8 2.3±1.8 0.345
Location (upper/mid/lower) 2/5/11 2/4/9 4/6/10 0.836
Visual pain scale (cm) 5.2±4.0 4.4±4.0 3.5±3.8 0.772
Operation time (min) 36.7±19.9 33.7±18.0 46.0±36.6 0.425
Foley catheter indwelling time (hours)  26.3±12.2 27.2±13.8 23.3±12.9 0.640
Stent indwelling duration (days) 9.9±4.9 9.4±6.4 11.4±5.5 0.562
Stone size (mm) 7.17±3.4 7.27±3.3 6.95±2.8 0.954
IPSS: International Prostate Symptom Score, QoL: quality of life, 
a: control group, patients were prescribed analgesics only, 
b: patients
were given 0.2 mg of tamsulosin and analgesics daily, 
c: patients took 0.2 mg of tamsulosin and 4 mg of tolterodine daily in addition
to analgesicsKorean J Urol 2010;51:636-641
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TABLE 3. Symptom changes in the appropriate stent group
POD Group 1
a Group 2
b (p-value
d)G r o u p  3
c (p-value
d)p - v a l u e
No. of patients 12 13 13
Total IPSS 1 15.2±6.6 7.4±6.7 (0.010) 11.7±7.7 (0.238) 0.040
7 13.3±8.3 10.2±10.4 (0.169) 9.9±8.9 (0.341) 0.609
Voiding symptom score  1 6.8±4.9 4.5±4.5 (0.242) 7.3±5.9 (0.828) 0.376
7 7.0±4.6 5.7±6.5 (0.695) 5.8±6.4 (0.587) 0.833
Storage symptom score  1 8.3±3.9 2.9±2.6 (0.001) 4.4±2.7 (0.009) 0.001
7 6.3±4.4 4.2±3.1 (0.356) 4.2±3.1 (0.182) 0.394
QoL score  1 4.0±1.2 3.2±1.5 (0.163) 3.8±1.7 (0.784) 0.387
7 3.3±1.6 3.2±2.0 (0.857) 3.2±2.0 (0.824) 0.972
Visual pain scale (cm)  1 5.0±2.3 3.4±3.1 (0.169) 5.0±3.3 (0.973) 0.326
7 3.0±2.0 3.5±3.2 (0.731) 3.8±2.5 (0.424) 0.774
POD: postoperative day, IPSS: International Prostate Symptom Score, QoL: quality of life, 
a: control group, patients were prescribed
analgesics only, 
b: patients were given 0.2 mg of tamsulosin and analgesics daily, 
c: patients took 0.2 mg of tamsulosin and 4 mg of tolter-
odine daily in addition to analgesics, 
d: p-value compared with group 1 by Student’s t-test
TABLE 4. Symptom changes in the inappropriate stent group
POD Group 1
a Group 2
b Group 3
c p-value
No. of patients 6 4 5
Total IPSS 1 12.8±7.4 15.8±14.2 6.4±1.8 0.277
7 17.3±7.0 21.8±8.9 15.4±5.9 0.438
Voiding  symptom score  1 7.5±4.6 8.5±9.0 2.6±2.1 0.249
7 8.0±5.6 12.0±7.7 7.8±3.6 0.488
Storage symptom score  1 5.3±3.3 7.3±7.4 3.8±3.0 0.551
7 9.3±2.5 9.8±4.4 7.6±2.9 0.556
QoL score  1 3.7±1.0 2.8±2.8 2.8±1.9 0.680
7 4.5±1.4 4.8±1.5 2.6±1.5 0.078
Visual pain scale (cm)  1 3.8±2.8 3.6±1.7 5.2±2.5 0.547
7 4.8±2.4 3.3±0.5 3.5±2.1 0.412
POD: postoperative day, IPSS: International Prostate Symptom Score, QoL: quality of life, 
a: control group, patients were prescribed
analgesics only, 
b: patients were given 0.2 mg of tamsulosin and analgesics daily, 
c: patients took 0.2 mg of tamsulosin and 4 mg of tolter-
odine daily in addition to analgesics
　The mean total IPSS showed no significant statistical 
difference in the three groups on the 1st postoperative day 
(14.5, 8.9, and 10.1, respectively; p＞0.05) or on the 7th 
postoperative day (14.2, 13.4, and 9.5, respectively; p＞
0.05). Voiding symptom scores also demonstrated no differ-
ence in the three groups on the 1st postoperative day (6.9, 
7.5, and 5.1, respectively; p＞0.05) or on the 7th post-
operative day (6.9, 5.0, and 5.7, respectively; p＞0.05). 
However, storage symptom scores were significantly lower 
in groups 2 and 3 than in group 1 on the 1st postoperative 
day (7.6, 3.9, and 4.4, respectively; p=0.014). The mean 
quality of life (QoL) scores and the mean VAS of the three 
groups on the 1st postoperative day were 3.9, 2.9, and 3.8 
(p＞0.05) and 4.6, 3.6, and 5.4, respectively (p＞0.05). On 
the 7th postoperative day, the mean QoL scores and the 
mean VAS were 3.8, 3.6, and 2.8 (p＞0.05) and 3.7, 3.4, and 
3.6, respectively (p＞0.05) (Table 2). The use of analgesics 
did not differ significantly among the groups.
　In the appropriate stent location group, the results were 
similar to the results of the total enrolled patients (Table 
3). On postoperative day 1 only, the patients taking tamsu-
losin showed improved total IPSS (p=0.01) and storage 
symptoms (p=0.001) and the patients taking tamsulosin 
and tolterodine showed improved storage symptoms 
(p=0.007) compared with the control group. However, an 
effect of medication was not observed in the inappropriate 
stent location group (Table 4).
　None of the patient who took tamsulosin 0.2 mg experi-
enced dizziness caused by orthostatic hypotension. Minor 
adverse effects including fatigue and dyspepsia occurred 
in two patients (13%), who were treated conservatively. In 
group 3, one patient experienced dry mouth and was also 
managed conservatively.
DISCUSSION
Ureteral stents have been widely used to manage various 
urinary tract diseases. Ureteral stents prevent urinary Korean J Urol 2010;51:636-641
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tract obstruction from ureteral swelling and divert urine. 
They also make the ureteral mucosa heal faster after iatro-
genic injury, dilate the ureter, and assist in stone passage 
[8]. However, many patients experience significant stent- 
related morbidities, and additional procedures are needed 
to remove the stent. 
　Although the pathophysiology of stent-related symp-
toms has not been clearly proved, Thomas suggested that 
the high pressure transmitted to the renal pelvis during 
micturition and trigonal irritation caused by the intra-
vesical portion of the stent may be contributing factors [9]. 
Deliveliotis et al reported that stent-related pain and uri-
nary frequency may be related to lower ureteral spasm or 
local trigone sensitivity [10]. 
　In the results of the current study, only storage symptom 
scores were significantly lower during the immediate post-
operative period in the treatment groups (group 2 and 
group 3) than in the control group. Although it was not sig-
nificant in the statistical analysis, a tendency for improved 
storage symptom scores in these groups was demonstrated 
on the 7th postoperative day. However, other parameters 
such as total IPSS, storage symptoms, voiding symptoms, 
QoL score, and VAS were not significantly different be-
tween the treatment groups and the control group irre-
spective of the duration after ureteroscopic ureterolithotomy. 
These findings are not consistent with those of recently re-
ported prospective trials that showed the effect of α-block-
ers and anticholinergics in preventing ureteral stent-re-
lated urinary tract symptoms, pain, and QoL during var-
iant periods from 3 days to 6 weeks [11-14]. It is hard to defi-
nitely conclude the efficacy of these agents on stent-related 
LUTS and pain. Therefore, future studies pooling these da-
ta will be needed to determine the overall treatment effect 
and the optimal management.
　Park et al reported that alfuzosin and tolterodine ER im-
proved stent-related urinary symptoms and body pain ac-
cording to the validated Ureteral Stent Symptom Questio-
nnaire (USSQ) [14]. There was no significant difference in 
urinary symptoms or pain between the alfuzosin and tol-
terodine ER groups. In our studies, there was no additional 
effect in the tamsulosin and tolterodine group compared 
with the tamsulosin only group. There are not many re-
ports about the role of anticholinergics; accordingly, fur-
ther study is needed to define the role of anticholinergics 
in stent-related morbidity.
　In our studies, stent-related LUTS were associated more 
with the location of the stent than with medication use dur-
ing the stent period. Therefore, the correct placement of a 
ureteral stent and verification of its location is important. 
Al-Kandari et al reported that flank pain was not affected 
by the length of the stent, whereas urgency, dysuria, and 
QoL were significantly affected [4].
　The potential limitations of the current study are as 
follows. First, even though the IPSS is the most widely used 
questionnaire for the assessment of LUTS, it is not specific 
for stent-related symptoms. Joshi et al first developed and 
validated a questionnaire for the evaluation of stent-re-
lated symptoms, the USSQ, which has good evaluative and 
discriminate properties [15]. Second, the number of pa-
tients in each group was relatively small, so the power to 
detect an effect was limited.
CONCLUSIONS
Stent-related LUTS were affected more by the location of 
the ureteral stent than by medication. When the stent posi-
tion was adequate, administration of tamsulosin or tolter-
odine combined with tamsulosin improved the storage 
symptoms only immediately after ureteroscopic ureteroli-
thotomy.
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